Anti-Angiopoietin-like 4 antibody
Specifications
| Product Cat#: | AB-06-0294 |
| Product type: | Primary antibody |
| Antigen: | Angiopoietin-like 4 |
| Immunogen: | This antibody is produced by immunizing rabbits with a synthetic peptide corresponding to an internal sequence of mouse angiopoietin-related protein 4. |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:400) |
| Reactivity: | Mouse |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer (pH7.4), 0.03% Proclin300 and 50% Glycerol. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A/G affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | Angiopoietin like 4 |
| Angiopoietin related protein 4 | |
| Angiopoietin-like protein 4 | |
| Angiopoietin-related protein 4 | |
| ANGL4_HUMAN | |
| ANGPT L2 | |
| ANGPT L4 | |
| ANGPTL2 | |
| ANGPTL4 | |
| ARP4 | |
| Fasting induced adipose factor | |
| FIAF | |
| Hepatic angiopoietin related protein | |
| Hepatic fibrinogen/angiopoietin related protein | |
| HFARP | |
| NL2 | |
| Peroxisome proliferator-activated receptor (PPAR) gamma induced angiopoietin related protein antibody PGAR | |
| Pp1158 | |
| PPARG angiopoietin related protein |
Target information
Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism (PubMed:19270337, PubMed:21398697, PubMed:27929370, PubMed:29899144). May also play a role in regulating glucose homeostasis and insulin sensitivity (Probable). Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage (PubMed:14583458, PubMed:17068295). Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro) (PubMed:17068295). Depending on context, may modulate tumor-related angiogenesis (By similarity).
Provider
Erpantech Laboratory
